OGT pushes forward hybridisation-based targeted sequencing

Oxford, UK – 25 May 2017. Oxford Gene Technology (OGT), The Molecular Genetics Company, has made several advances in hybridisation-based target enrichment protocols that now enable researchers to prepare samples for sequencing in just one day. Researchers can now access the high-quality results of hybridisation-based targeted sequencing with a speed comparable to that of amplicon-based approaches.

OGT’s hybridisation-based targeted sequencing delivers unparalleled coverage uniformity enabling researchers to detect low frequency variants consistently down to 1% VAF (variant allele frequency) at a read depth of >1000x. The company’s latest protocol developments enable even more researchers to quickly and precisely focus in on regions relevant to their research - increasing throughput and confidence in results while saving on time and reagents.

OGT’s hybridisation assay enhancements improve speed and also enable lower input levels of DNA to be used. The company has optimised its enzymes and buffers to allow pooling of library preparation steps enabling users to complete the whole enrichment protocol in less time. This includes a short enzymatic fragmentation step, combined end-repair and adaptor ligation steps, and an optimised hybridisation of just 30 minutes for good quality DNA samples. In addition, OGT’s NGS panel optimisation yields good data with as little as 10 ng of starting material*.

Dave Cook, Senior Product Manager at OGT, elaborated, “OGT was founded by Professor Sir Edwin Southern — inventor of the Southern Blot — so the company is, at its very core, a hybridisation company. This permeates through everything we do and gives us a very unique level of expertise. It’s clear that our hybridisation-based target enrichment has many advantages over amplicon methods in terms of quality and the ability to sequence through difficult regions,   protocol length was a further area for improvement. Now, thanks to our efforts, hybridisation has moved forward and we are in a position where we can take users from sample to sequencer in a single day, enabling more researchers to gain the benefits of our technology. We are committed to continue pushing hybridisation-based technologies forward to help our customers achieve their goals.”

OGT has also recently expanded its fully tested and optimised SureSeq myPanel™ NGS Custom Cancer Panel content, covering both haematology and solid tumours. The new content provides optimised coverage for over 90 genes, including difficult-to-sequence genes and other regions.

For more information please visit www.ogt.com.

*In-house validation required

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.

T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684

E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech


DiaSorin and Tecan to collaborate in new platform development

DiaSorin and Tecan Group have announced that they have agreed to collaborate in a development under ...

Read More >

Genedrive Receives NHS Grant

The UK NHS National Institute for Health Research in June 2018 have offered Professor Bill Newman an...

Read More >

Cytox in Collaboration with AKESOgen Extends Genetic Test for Assessing Alzheimer's Disease

8th May 2018: Oxford & Manchester, UK and Atlanta, GA. Cytox, a precision medicine testing company ...

Read More >

EKF to highlight Lucica® Glycated Albumin-L assay for diabetes patient monitoring at AACC 2019

Specific, intermediate glycemic control marker for diabetes at EKF’s Booth #2952 at AACC 2019 Clini...

Read More >

Radiometer helps enhance patient outcomes at the University of Leicester Hospitals NHS Trust

Crawley, UK – 15 February 2018 – Radiometer Ltd has implemented its AQURE Enterprise point-of-care...

Read More >

EKF Publishes Guide to Good Capillary Blood Sampling

Incorrect capillary blood sampling is most common reason for inaccurate POC hemoglobin results

Read More >